Combinatorial pharmacogenomic (CPGx) GeneSight method predicts healthcare outcomes better than traditional, single-gene analysis.

“Multigenic combinatorial testing discriminates and predicts the poorer antidepressant outcomes and greater health-care utilizations by depressed subjects better than do phenotypes derived from single genes.”

Altar CA, et al. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J 2015; 15:443-51.

Learn More View Article